During the past decade, Médipôle de Savoie conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 2 clinical trials were completed, i.e. on average, 11.8% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 2 clinical trials were completed. i.e. 28.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Médipôle de Savoie" #1 sponsor was "Federation Francophone de Cancerologie Digestive" with 4 trials, followed by "The Lymphoma Academic Research Organisation" with 4 trials sponsored, "ARCAGY/ GINECO GROUP" with 2 trials sponsored, "Centre Hospitalier Universitaire de Saint Etienne" with 2 trials sponsored and "Hospira, now a wholly owned subsidiary of Pfizer" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Médipôle de Savoie" #1 collaborator was "GERCOR - Multidisciplinary Oncology Cooperative Group" with 2 trials as a collaborator, "ARCAGY/ GINECO GROUP" with 1 trials as a collaborator, "Association de Neuro-Oncologues d'Expression Francaise" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Bayer" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Médipôle de Savoie" are "Aneurysm" (1 trials), "Anterior Cruciate Ligament Rupture" (1 trials), "Aortic Aneurysm" (1 trials), "Aortic Aneurysm, Abdominal" (1 trials) and "Aortic Diseases" (1 trials). Many other conditions were trialed in "Médipôle de Savoie" in a lesser frequency.

Most popular intervention types in "Médipôle de Savoie" are "Drug" (13 trials), "Biological" (2 trials), "Device" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bevacizumab" (2 trials), "Lenalidomide" (2 trials), "Nivestim®" (2 trials), "Oxaliplatin" (2 trials) and "Rituximab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Médipôle de Savoie" are 17 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Médipôle de Savoie". undefined are not yet recruiting, 6 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Médipôle de Savoie, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Médipôle de Savoie, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".

Médipôle de Savoie has several departments that took part in Clinical trials: "Medipole De Savoie; Departement Oncologie" - 3 trials